Citations

Clear

623 citation(s) found for "Torres, V".

DOP16 Anti-integrin αvβ6 autoantibodies predate Ulcerative Colitis diagnosis by up to 10 years and are associated with adverse disease-related outcomes
Fischer, J , Lee, S H , Rui, Sew Xin, Jougon, Julia, Riddle, Mark S. , Laird, Renée M. , Torres, J , Magee, Jared , Sheppard, D., Sands, B E, Porter, Chad K., Croitoru, Kenneth , Petralia, Francesca , Colombel, J F, Mehandru, Saurabh , Livanos, Alexandra E. , Dunn, A, Ungaro, Ryan C. , Turpin, Williams , Valle, Diane M. Del , Martínez-Delgado, Gustavo , Murray, Joseph A. , Agrawal, Manasi , Dervieux, Thierry , Gnjatic, Sacha , Porter, Chad K.

Mayo Clinic

Journal of Crohn's and Colitis | January 30, 2023 | Volume: 17 | Issue: Supplement_1 | Pages: i79-i80

10.1093/ecco-jcc/jjac190.0056 Get It

Abstract Background Biomarkers for predicting the development of Ulcerative Colitis (UC) and disease-related complications are lacking. Anti-integrin αvβ6 IgG autoantibodies (anti-αvβ6) have been recently described in patients diagnosed with UC. Here, we sought to determine if anti-αvβ6 autoantibodies predate UC development and to study associations between anti-αvβ6 and disease outcomes in newly diagnosed UC patients. Methods In a unique pre-clinical IBD cohort from the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS), anti-αvβ6 were measured in longitudinal pre-diagnosis serum samples from 82 subjects who later developed UC as well as in 82 matched subjects that did not develop IBD (HC). Sample A was at the time of UC diagnosis, Sample B was at a median of 2 years before Sample A, Sample C was at a median of 4 years before Sample A and Sample D was at a median of 10 years before Sample A. In a distinct, external validation cohort (the Crohn’s and Colitis Canada Genetics Environment Microbial (GEM) Project), we tested samples from 12 subjects who later developed UC and compared those with 49 matched subjects who remained asymptomatic. Further, anti-αvβ6 were measured in 2 incident IBD cohorts (COMPASS, n=55 and OSCCAR, n=104 UC subjects) and associations between anti-αvβ6 and adverse UC-outcomes were defined using Cox proportional-hazards model. Results Anti-αvβ6 were significantly higher in the PREDICTS cohort among individuals who developed UC compared to HC up to 10 years prior to diagnosis (Figure 1A). The anti-αvβ6 seropositivity was 12.2% 10 years before diagnosis and increased to 52.4% at the time of diagnosis in subjects who developed UC compared with 2.7% in controls across the 4 timepoints. Additionally, the predictive performance of anti-αvβ6 autoantibodies as assessed via area under the receiver operator curves (AUROC) with 10-fold cross validation was at least 0.8 up to 10 years before diagnosis (Figure 1B). Elevated levels of anti-αvβ6 in pre-clinical UC samples were further validated in the GEM cohort (Figure 1C). Finally, high anti-αvβ6 were associated with a composite of adverse UC-outcomes including hospitalization, disease extension, colectomy, systemic steroid use and/or escalation to biologic therapy in both incident cohorts (Figure 1D). Conclusion Anti-integrin αvβ6 autoantibodies precede the clinical diagnosis of UC by up to 10 years and are associated with adverse UC-related outcomes.
Smartphones and Threshold-Based Monitoring Methods Effectively Detect Falls Remotely: A Systematic Review
Torres‐Guzman, Ricardo A. , Maita, Karla C. , Maniaci, Michael J. , Paulson, Margaret R. , Maita, Karla , Maniaci, Michael J , Torres, Ricardo A , Ávila, Francisco R. , Garcia, John P. , Forte, Antonio J.

Mayo Clinic

Sensors | January 25, 2023 | Volume: 23 | Issue: 3 | Pages: 1323

10.3390/s23031323 | PMID 36772364 Get It

In the US, at least one fall occurs in at least 28.7% of community-dwelling seniors 65 and older each year. Falls had medical costs of USD 51 billion in 2015 and are projected to reach USD 100 billion by 2030. This review aims to discuss the extent of smartphone (SP) usage in fall detection and prevention across a range of care settings. A computerized search was conducted on six electronic databases to investigate the use of remote sensing technology, wireless technology, and other related MeSH terms for detecting and preventing falls. After applying inclusion and exclusion criteria, 44 studies were included. Most of the studies targeted detecting falls, two focused on detecting and preventing falls, and one only looked at preventing falls. Accelerometers were employed in all the experiments for the detection and/or prevention of falls. The most frequent course of action following a fall event was an alarm to the guardian. Numerous studies investigated in this research used accelerometer data analysis, machine learning, and data from previous falls to devise a boundary and increase detection accuracy. SP was found to have potential as a fall detection system but is not widely implemented. Technology-based applications are being developed to protect at-risk individuals from falls, with the objective of providing more effective and efficient interventions than traditional means. Successful healthcare technology implementation requires cooperation between engineers, clinicians, and administrators.
Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort
Vollstedt, Eva‐Juliane , Schaake, Susen , Lohmann, Katja , Lesage, Suzanne , Tesson, Christelle , Wurster, Isabel , Hentati, F., Marder, Karen, Waters, Cheryl , Fahn, Stanley, Brüggemann, Norbert , Tolosa, Eduardo , Garrido, Alícia , Annesi, Grazia , Bozi, Maria , Ferreira, Joaquim J. , Guedes, Leonor Correia , Petrucci, Simona , Clark, Lorraine N. , Abramycheva, Natalya, Menéndez‐González, Manuel , Maestre, S. Jesús, Gómez‐Garre, Pilar , Mir, Pablo , Ran, Caroline , Kuo, Ming‐Che , Ross, Owen A. , Williams‐Gray, Caroline H. , Camacho, Marta , Cornejo‐Olivas, Mario , Torres-Ramírez, Luis , Wu, Yih‐Ru , Morgadinho, Ana , Berg, Daniela , Kuhlenbäumer, Gregor , Kühn, Andrea A. , Borngräber, Friederike , Michele, Giuseppe De , Rosa, Anna De , Zimprich, Alexander , Puschmann, Andreas , Mellick, George D. , Chase, Bruce A. , Markopoulou, Katerina , Satake, Wataru , Rossi, Malco , Lynch, Timothy , Olszewska, Diana A. , Lim, Shen‐Yang , Ahmad‐Annuar, Azlina , Tan, Ai Huey , Hanağası, Haşmet , Koziorowski, Dariusz , Ertan, Sibel , Genç, Gençer , Saunders‐Pullman, Rachel , Warrenburg, Bart van de, Bressman, Susan , Toft, Mathias , Appel‐Cresswell, Silke , Boon, Agnita J.W. , Krüger, Rejko , Sammler, Esther , Tumas, Vítor , Zhang, Baorong , Garraux, Gaëtan , Kim, Yun Joong , Winkelmann, Juliane , Sue, Carolyn M. , Tan, Eng‐King , Kostić, Vladimir , Arkadir, David , Martikainen, Mika H. , Brighina, Laura , Suchowersky, Oksana , Rieß, Olaf , Das, Parimal, Mollenhauer, Brit , Gatto, Emilia , Petersen, Maria Skaalum , Aasly, Jan , Aasly, Anna, Farrer, Matthew J. , Brockmann, Kathrin , Klein, Christine , Group, the MJFF Global Genetic Parkinson's Disease Study, Bardien, Soraya , Barrett, Matthew J. , Januário, Cristina , Sousa, Mário , Soto‐Beasley, Alexandra I. , May, Patrick , Mirelman, Anat , Brüggemann, Norbert , Borsche, Max , Tolosa, Eduardo , Ferreira, Joaquim J , Alvarez, Victoria , Mir, Pablo , Kuo, Ming-Che , Ross, Owen A , Nishioka, Kenya , Williams-Gray, Caroline H , Camacho, Marta , Cornejo-Olivas, Mario , Wu, Yih-Ru , Termsarasab, Pichet , Borngräber, Friederike , Zimprich, Alexander , Gambardella, Stefano , Chase, Bruce , Olszewska, Diana A , Tan, Ai Huey , Barkhuizen, Melinda , Appel-Cresswell, Silke , Skorvanek, Matej , Sammler, Esther M , Zhang, Baorong , Chung, Sun Ju , Puschmann, Andreas , Januário, Cristina , Klein, Christine , Bardien, Soraya , Toft, Mathias , Koziorowski, Dariusz , May, Patrick , Beasley, Alexandra I , Barrett, Matthew J , Sue, Carolyn M , Kühn, Andrea A , Padmanabhan, Shalini , Brice, Alexis , Vidailhet, Marie , Giladi, Nir , Kasten, Meike , Borsche, Max , Foroud, Tatiana , Gagliardi, Monica , Stefanis, Leonidas , Avenali, Micol , Fedotova, E. Yu. , Álvarez, Victoria , Belin, Andrea Carmine , Lin, Chin‐Hsien , Crosiers, David , Wszołek, Zbigniew K. , Jankovic, Joseph J. , Funayama, Manabu , Clarimón, Jordi , Lee‐Chen, Guey‐Jen , Pulkes, Teeratorn , Dorszewska, Jolanta , Carr, Jonathan , Ferese, Rosangela , Toda, Tatsushi , Merello, Marcelo , Al-Mubarak, Bashayer R , Aguiar, Patrícia de Carvalho , Pimentel, Márcia Mattos Gonçalves , Warrenburg, Bart P.C. van de , Lang, Anthony E. , Damásio, Joana , Klivènyi, Péter , Borges, Vanderci , Hertz, Jens Michael , Spitz, Mariana , Hattori, Nobutaka , Wu, Ruey‐Meei , Illarioshkin, Sergey Nikolaevich , Valente, Enza Maria , Alcalay, Roy N. , Thaler, Avner , Corvol, Jean‐Christophe , Group, the MJFF Global Genetic Parkinson's Disease Study

Mayo Clinic

Movement Disorders | January 24, 2023 | Volume: 38 | Issue: 2 | Pages: 286-303

10.1002/mds.29288 | PMID 36692014 Get It

AbstractBackgroundAs gene‐targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial‐ready cohorts is limited.ObjectiveThe objectives are to (1) establish an international cohort of affected and unaffected individuals with PD‐linked variants; (2) provide harmonized and quality‐controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD.MethodsWe conducted a worldwide, systematic online survey to collect individual‐level data on individuals with PD‐linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ‐1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed.ResultsWe collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ‐1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published.ConclusionsWithin the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD‐linked variants; (2) provide harmonized and quality‐controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene‐targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Comparing Complication Rates of Midline Catheter vs Peripherally Inserted Central Catheter. A Systematic Review and Meta-analysis
Urtecho, Meritxell , Roldan, Victor D. Torres , Nayfeh, Tarek , Ranganath, Nischal , Sampathkumar, Priya , Safdar, Nasia , Torres Roldan, Victor D , Ranganath, Nischal , Nayfeh, Tarek , Suárez, Nataly R. Espinoza , Chopra, Vineet , Prokop, Larry J. , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | January 18, 2023 | Volume: 10 | Issue: 2 | Pages: No page available

10.1093/ofid/ofad024 | PMID 36751645 Get It

Abstract Background Peripherally inserted central catheters (PICCs) and midlines are commonly used devices for reliable vascular access. Infection and thrombosis are the main adverse effects of these catheters. We aimed to evaluate the relative risk of complications from midlines and PICCs. Methods We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies. The primary outcomes were catheter-related bloodstream infection (CRBSI) and thrombosis. Secondary outcomes evaluated included mortality, failure to complete therapy, catheter occlusion, phlebitis, and catheter fracture. The certainty of evidence was assessed using the GRADE approach. Results Of 8368 citations identified, 20 studies met the eligibility criteria, including 1 RCT and 19 observational studies. Midline use was associated with fewer patients with CRBSI compared with PICCs (odds ratio [OR], 0.24; 95% CI, 0.15–0.38). This association was not observed when we evaluated risk per catheter. No significant association was found between catheters when evaluating risk of localized thrombosis and pulmonary embolism. A subgroup analysis based on location of thrombosis showed higher rates of superficial venous thrombosis in patients using midlines (OR, 2.30; 95% CI, 1.48–3.57). We did not identify any significant difference between midlines and PICCs for the secondary outcomes. Conclusions Our findings suggest that patients who use midlines might experience fewer CRBSIs than those who use PICCs. However, the use of midline catheters was associated with greater risk of superficial vein thrombosis. These findings can help guide future cost-benefit analyses and direct comparative RCTs to further characterize the efficacy and risks of PICCs vs midline catheters.
Impact of an Acquisition Advanced Practice Provider on Home Hospital Patient Volumes and Length of Stay
Felix, Heidi, Cowdell, Jed C. , Maita, Karla C. , Dugani, Sagar B. , Matcha, Gautam , Maniaci, Michael J. , Felix, Heidi M, Paulson, Margaret R. , Dugani, Sagar B , Torres-Guzman, Ricardo A, Matcha, Gautam V , Maniaci, Michael J , Felix, Heidi M., Ávila, Francisco R. , Torres‐Guzman, Ricardo A. , Forte, Antonio J.

Mayo Clinic

Healthcare | January 17, 2023 | Volume: 11 | Issue: 3 | Pages: 282

10.3390/healthcare11030282 | PMID 36766857 Get It

In July 2020, Mayo Clinic introduced a hospital-at-home program, known as Advanced Care at Home (ACH) as an alternate option for clinically stable medical patients requiring hospital-level care. This retrospective cohort study evaluates the impact of the addition of a dedicated ACH patient acquisition Advanced Practice Provider (APP) on average length of stay (ALOS) and the number of patients admitted into the program between in Florida and Wisconsin between 6 July 2020 and 31 January 2022. Patient volumes and ALOS of 755 patients were analyzed between the two sites both before and after a dedicated acquisition APP was added to the Florida site on 1 June 2021. The addition of a dedicated acquisition APP did not affect the length of time a patient was in the emergency department or hospital ward prior to ACH transition (2.91 days [Florida] vs. 2.59 days [Wisconsin], p = 0.22), the transition time between initiation of the ACH consult to patient transfer home (0.85 days [Florida] vs. 1.16 days [Wisconsin], p = 0.28), or the total ALOS (6.63 days [Florida] vs. 6.34 days [Wisconsin], p = 0.47). The average number of patients acquired monthly was significantly increased in Florida (38.3 patients per month) compared with Wisconsin (21.6 patients per month) (p < 0.01). The addition of a dedicated patient acquisition APP resulted in significantly higher patient volumes but did not affect transition time or ALOS. Other hospital-at-home programs may consider the addition of an acquisition APP to maximize patient volumes.
Treatment of a high healthcare utilizer with sepsis in a virtual hybrid hospital‐at‐home program
Paulson, Margaret R. , Torres‐Guzman, Ricardo A. , Matcha, Gautam , Ávila, Francisco R. , Maita, Karla C. , Garcia, John P. , Maniaci, Michael J. , Matcha, Gautam V , Forte, Antonio Jorge , Maniaci, Michael J , Torres, Ricardo A , Avila, Francisco R , Garcia, John P , Paulson, Margaret R , Forte, Antonio J.

Mayo Clinic

Clinical Case Reports | January 4, 2023 | Volume: 11 | Issue: 1 | Pages: No page available

10.1002/ccr3.6806 | PMID 36619489 Get It

Abstract High healthcare utilizers are often chronically ill patients who require aggressive hospital and outpatient care. We describe a patient with septic shock who was stabilized in the intensive care unit, then transitioned to a virtual hybrid hospital‐at‐home to complete both inpatient care as well as outpatient wound and rehabilitation therapy.
Genome-wide Interaction Study with Smoking for Colorectal Cancer Risk Identifies Novel Genetic Loci Related to Tumor Suppression, Inflammation, and Immune Response
Carreras‐Torres, Robert , Kim, Andre E. , Lin, Yi , Díez‐Obrero, Virginia , Bien, Stephanie A. , Qu, Conghui , Dimou, Niki , Aglago, Elom K. , Albanes, Demetrius , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Drew, David A. , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jordahl, Kristina M. , Kundaje, Anshul , Li, Li , Nan, Hongmei , Nassir, Rami , Obón‐Santacana, Mireia , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , Weinstein, Stephanie J. , White, Emily , Woods, Michael O. , Peters, Ulrike , Gauderman, W. James , Wang, Jun , Dimou, Niki , Aglago, Elom K , Albanes, Demetrius , Arndt, Volker , Baurley, James W , Berndt, Sonja I , Bézieau, Stéphane , Bishop, D Timothy , Bouras, Emmanouil , Brenner, Hermann , Budiarto, Arif , Campbell, Peter T , Casey, Graham , Chan, Andrew T , Chang-Claude, Jenny , Chen, Xuechen , Conti, David V , Dampier, Christopher H , Devall, Matthew A M , Drew, David A , Figueiredo, Jane C , Gallinger, Steven , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Harrison, Tabitha A , Hidaka, Akihisa , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Kawaguchi, Eric , Keku, Temitope O , Kundaje, Anshul , Marchand, Loïc Le , Lewinger, Juan Pablo , Li, Li , Mahesworo, Bharuno , Morrison, John L , Murphy, Neil , Nan, Hongmei , Nassir, Rami , Newcomb, Polly A. , Obón-Santacana, Mireia , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Papadimitriou, Nikos , Pardamean, Bens , Peoples, Anita R , Pharoah, Paul D P , Platz, Elizabeth A. , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Scacheri, Peter C , Schmit, Stephanie L , Schoen, Robert E , Shcherbina, Anna , Slattery, Martha L , Stern, Mariana Carla , Su, Yu-Ru , Tangen, Catherine M , Thomas, Duncan C , Tian, Yu , Tsilidis, Konstantinos K , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Vodicka, Pavel , Cenggoro, Tjeng Wawan , Weinstein, Stephanie J , White, Emily , Wolk, Alicja , Woods, Michael O , Hsu, Li , Peters, Ulrike , Moreno, Victor , Gauderman, W James , Bien, Stephanie A , Carreras-Torres, Robert , Diez-Obrero, Virginia , Qu, Conghui , Arndt, Volker , Bezieau, Stéphane , Campbell, Peter T. , Chan, Andrew T. , Conti, David V. , Dampier, Christopher H. , Giles, Graham G. , Gunter, Marc J. , Hidaka, Akihisa , Jenkins, Mark A. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Morrison, John L. , Murphy, Neil , Palmer, Julie R. , Pardamean, Bens , Pharoah, Paul D.P. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Shcherbina, Anna , Tangen, Catherine M. , Tian, Yu , Tsilidis, Konstantinos K. , Ulrich, Cornelia M. , Wolk, Alicja , Moreno, Vı́ctor

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 28, 2022 | Volume: 32 | Issue: 3 | Pages: 315-328

10.1158/1055-9965.epi-22-0763 | PMID 36576985 Get It

Abstract Background: Tobacco smoking is an established risk factor for colorectal cancer. However, genetically defined population subgroups may have increased susceptibility to smoking-related effects on colorectal cancer. Methods: A genome-wide interaction scan was performed including 33,756 colorectal cancer cases and 44,346 controls from three genetic consortia. Results: Evidence of an interaction was observed between smoking status (ever vs. never smokers) and a locus on 3p12.1 (rs9880919, P = 4.58 × 10−8), with higher associated risk in subjects carrying the GG genotype [OR, 1.25; 95% confidence interval (CI), 1.20–1.30] compared with the other genotypes (OR &lt;1.17 for GA and AA). Among ever smokers, we observed interactions between smoking intensity (increase in 10 cigarettes smoked per day) and two loci on 6p21.33 (rs4151657, P = 1.72 × 10−8) and 8q24.23 (rs7005722, P = 2.88 × 10−8). Subjects carrying the rs4151657 TT genotype showed higher risk (OR, 1.12; 95% CI, 1.09–1.16) compared with the other genotypes (OR &lt;1.06 for TC and CC). Similarly, higher risk was observed among subjects carrying the rs7005722 AA genotype (OR, 1.17; 95% CI, 1.07–1.28) compared with the other genotypes (OR &lt;1.13 for AC and CC). Functional annotation revealed that SNPs in 3p12.1 and 6p21.33 loci were located in regulatory regions, and were associated with expression levels of nearby genes. Genetic models predicting gene expression revealed that smoking parameters were associated with lower colorectal cancer risk with higher expression levels of CADM2 (3p12.1) and ATF6B (6p21.33). Conclusions: Our study identified novel genetic loci that may modulate the risk for colorectal cancer of smoking status and intensity, linked to tumor suppression and immune response. Impact: These findings can guide potential prevention treatments.
Perceived Age in Patients Exposed to Distinct UV Indexes: A Systematic Review
Ávila, Francisco R. , Carter, Rickey E. , Giardi, Davide , Guliyeva, Günel , Torres‐Guzman, Ricardo A. , Maita, Karla C. , Bruce, Charles J. , Giardi, Davide , Torres, Ricardo A , Forte, Antonio Jorge , Carter, Rickey E , Avila, Francisco R , McLeod, Christopher J. , Forte, Antonio J.

Mayo Clinic

Indian Journal of Plastic Surgery | December 22, 2022 | Volume: 56 | Issue: 02 | Pages: 103-111

10.1055/s-0042-1759696 | PMID 37153341 Get It

AbstractPhotodamage is caused by chronic sun exposure and ultraviolet radiation and presents as wrinkles, sagging, and pigmented spots. An increase in the ultraviolet index can increase a person's perceived age by worsening skin photodamage. However, since the ultraviolet index varies considerably between geographical regions, perceived age might vary substantially among them. This review aims to describe the differences in chronological and perceived age in regions of the world with different ultraviolet indexes. A literature search of three databases was conducted for studies analyzing perceived age and its relationship to sun exposure. Ultraviolet indexes from the included studies were retrieved from the National Weather Service and the Tropospheric Emission Monitoring Internet Service. Out of 104 studies, seven fulfilled the inclusion criteria. Overall, 3,352 patients were evaluated for perceived age. All studies found that patients with the highest daily sun exposures had the highest perceived ages for their chronological age (p < 0.05). People with high sun exposure behaviors living in regions with high ultraviolet indexes will look significantly older than same-aged peers living in lower ultraviolet index regions.
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Visvanathan, Kala , Cope, Leslie , Fackler, Mary Jo , Considine, Michael , Sokoll, Lori J. , Carey, Lisa A. , Forero-Torres, Andres , Ingle, James N. , Lin, Nancy U. , Nanda, Rita , Storniolo, Anna Maria , Tulac, Suzana , Venkatesan, Neesha , Wu, Natalie C. , Marla, Sudhakar , Campbell, Scott , Bates, Michael , Umbricht, Christopher B. , Ingle, J , Sokoll, Lori , Wolff, Antonio C , Sukumar, Saraswati , Carey, Lisa A , Visvanathan, Kala , Lin, Nancy U , Wolff, Antonio C.

Mayo Clinic

Clinical Cancer Research | December 19, 2022 | Volume: 29 | Issue: 4 | Pages: 784-790

10.1158/1078-0432.ccr-22-2128 | PMID 36534524 Get It

Abstract Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay using the GeneXpert cartridge system for early assessment of disease progression in MBC. Experimental Design: The 9-marker LBx-BCM prototype assay was evaluated in TBCRC 005, a prospective biomarker study, using plasma collected at baseline, week 4, and week 8 from 144 patients with MBC. Results: At week 4, patients with MBC with high cumulative methylation (CM) had a significantly shorter median PFS (2.88 months vs. 6.60 months, P = 0.001) and OS (14.52 months vs. 22.44 months, P = 0.005) compared with those with low CM. In a multivariable model, high versus low CM was also associated with shorter PFS (HR, 1.90; 95% CI, 1.20–3.01; P = 0.006). Change in CM from baseline to week 4 (OR, 4.60; 95% CI, 1.77–11.93; P = 0.002) and high levels of CM at week 4 (OR, 2.78; 95% CI, 1.29–5.99; P = 0.009) were associated with progressive disease at the time of first restaging. A robust risk model based on week 4 circulating CM levels was developed to predict disease progression as early as 3 months after initiating a new treatment. Conclusions: The automated LBx-BCM prototype assay is a promising clinical tool for detecting disease progression a month after initiating treatment in women with MBC undergoing routine care. The next step is to validate its clinical utility for specific treatments.
Angiosarcoma arising in a schwannoma of the peripheral nervous system: illustrative case
Lakomkin, Nikita , Torres‐Mora, Jorge , Dozois, Eric J. , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | December 19, 2022 | Volume: 4 | Issue: 25 | Pages: No page available

10.3171/case22452 | PMID 36536527 Get It

BACKGROUND Schwannomas of the peripheral nerves are benign tumors that can very rarely undergo malignant transformation. These lesions are particularly challenging to diagnose via noninvasive techniques but can have significant implications for treatment. OBSERVATIONS This is a case of a 70-year-old female with a prior history of a right sciatic notch tumor that was diagnosed as a conventional schwannoma via histology from an initial biopsy and subsequent surgical debulking. Unfortunately, she experienced significant worsening of her motor deficit, whereby her postoperative foot weakness progressed to complete foot drop in less than 2 years. In addition, she demonstrated significant radiological progression, with more than 1 to 2 cm of growth in each dimension at her subsequent evaluation, along with intractable right leg pain. An additional operation was performed to completely remove the 7 × 8 cm tumor, and histology demonstrated angiosarcoma within a schwannoma. There was no evidence of recurrence at 15 months, and the patient had significant improvement in her pain. LESSONS Rapidly worsening function and radiological progression are not typically seen with conventional benign nerve sheath tumors and should prompt consideration of other lesions. Angiosarcoma within schwannoma is a rare pathology and optimal therapies for these tumors in terms of surgical timing and adjuvant therapy are still unknown.